Gilead Sciences, Inc. to Post Q4 2018 Earnings of $1.88 Per Share, William Blair Forecasts (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at William Blair boosted their Q4 2018 EPS estimates for shares of Gilead Sciences in a research note issued to investors on Wednesday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings of $1.88 per share for the quarter, up from their prior forecast of $1.78. William Blair currently has a “Buy” rating on the stock.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.70 earnings per share.
Gilead Sciences (GILD) traded up $0.82 during midday trading on Monday, reaching $80.14. 10,030,600 shares of the company were exchanged, compared to its average volume of 9,953,158. The company has a market capitalization of $104,740.00, a PE ratio of 23.12, a P/E/G ratio of -1.77 and a beta of 1.22. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Welch Investments LLC bought a new stake in shares of Gilead Sciences during the third quarter worth $108,000. Wealthcare Advisory Partners LLC bought a new stake in shares of Gilead Sciences during the third quarter worth $133,000. Horan Capital Advisors LLC. bought a new stake in shares of Gilead Sciences during the third quarter worth $144,000. Hanson & Doremus Investment Management increased its position in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences during the second quarter worth $147,000. Institutional investors own 76.47% of the company’s stock.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the sale, the executive vice president now directly owns 70,988 shares in the company, valued at $5,298,544.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman John C. Martin sold 50,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the sale, the chairman now owns 3,046,766 shares in the company, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders sold 358,333 shares of company stock worth $28,066,908 over the last 90 days. 1.30% of the stock is currently owned by company insiders.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 2.85%. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is currently 59.77%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.